INNOPHARMA LABS LIMITED

Their core work

InnoPharma Labs is an Irish pharma-technology SME that builds intelligent, closed-loop control and monitoring systems for core pharmaceutical manufacturing steps. Their work targets two of the most critical unit operations in solid-dose and API production — fluidised bed granulation and API crystallisation — bringing real-time sensing, machine intelligence and self-guided control into environments traditionally dominated by manual recipes and offline QC. In practice, this means helping pharmaceutical manufacturers make better granules and purer, more consistent active ingredients with less waste, fewer failed batches and tighter process understanding. Their value to a scientist or business partner is deep, application-specific expertise at the intersection of pharma engineering, PAT and industrial AI.

What they specialise in

How they've shifted over time

Their first H2020 project (SMART-GRAN, 2015-2017) focused on a specific downstream unit operation — fluidised bed granulation — with a self-guided control concept. By the second project (SmartCrys, 2019-2021) they had moved upstream in the pharma value chain to API crystallisation, applying a similar philosophy of advanced intelligence and closed-loop control. The clear trajectory is from one unit operation to a broader, smarter pharma-manufacturing control platform covering multiple critical steps.

They are heading toward a platform approach to intelligent pharmaceutical manufacturing — extending self-guided control across multiple unit operations — which makes them a strong fit for partners planning continuous or digitalised API and drug-product lines.

How they like to work

Both H2020 projects were led as sole coordinator under the SME Instrument Phase 2 scheme, which is designed for single-company innovation projects rather than large consortia. This means they are used to driving their own R&D agenda and managing EU-funded development end-to-end, but they do not have a visible history of multi-partner H2020 consortium work. Partners looking for a technology-owning SME to bring in as a specialist supplier will find them well-suited; those looking for a hub coordinator of large consortia will not.

As a sole-coordinator SME Instrument beneficiary, they show no H2020 consortium partners in the data, so their visible EU network is limited; their collaboration footprint is more likely to sit in direct commercial relationships with pharmaceutical manufacturers across Europe and globally.

What sets them apart

Most SMEs in pharma manufacturing offer either hardware or software; InnoPharma Labs has twice won competitive SME Phase 2 funding specifically to deliver self-guided, closed-loop control systems for regulated unit operations (granulation, crystallisation). They sit in Ireland's dense pharma cluster but are focused on the intelligence layer rather than being a contract manufacturer, which is a relatively uncommon profile. For a partner who needs deep, pharma-specific process control expertise rather than generic Industry 4.0 services, they are a natural choice.

Highlights from their portfolio

• SMART-GRAN
  Sole-coordinated EUR 1.72M SME Phase 2 project to commercialise a self-guided fluidised bed granulation solution — a rare example of an SME bringing autonomous control to a standard pharma unit operation.
• SmartCrys
  EUR 1.61M SME Phase 2 project extending the same closed-loop, intelligent-control philosophy from granulation to API crystallisation, signalling a platform strategy rather than a single-product company.